TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01791868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Sodium Valproate
Description: According to randomization arm, patients will be treated either by intravenous sodium valproate (30 mg/kg during 15 min then 1 mg/kg/h during 12 h) or intravenous placebo. All included patients will benefit from first-line anti epileptic drugs and symptomatic medical care, in agreement with the French Experts Recommendation 2009(RFE 2009).
Study: NCT04238546

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sirolimus-coated balloon catheter
Description: angioplasty with sirolimus-coated balloon catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: uncoated balloon catheter
Description: angioplasty with uncoated balloon catheter
Study: NCT03891446

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care treatment based on investigator's judgement.
Study: NCT00881335

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: flutter mucus clearance device
Description: five minutes every sessions, three sessions per day
Study: NCT01963026

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ToCUEST featuring a 'variable practice' approach.
Description: Intervention Variable practice: The ToCUEST (Task-Oriented Client-centred Upper Extremity Skill Training) module \[17\] will be given to the participants, in which individual goals will be extracted using the COPM (Canadian Occupational Performance Measure). The training program will start with a task analysis and is based on principles of training physiology and motor learning, including variability practice, random practice, distribution based practice, feedback, whole learning. A detailed description of the ToCUEST module is given in Spooren et al. \[17\]. Intervention B will be called 'ToCUEST variability' in the present project.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ToCUEST featuring a 'constant practice' approach.
Description: Intervention Constant practice: In order to evaluate the contribution of the component 'variability practice' in contrast with 'constant practice' the participants will be offered the modified ToCUEST ('ToCUEST constant') module in which the component 'variability practice' is replaced by 'constant practice'.
Study: NCT01521585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEN0014196
Description: 50 mg oral once daily tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEN0014196
Description: 200 mg oral once daily tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral once daily tablet
Study: NCT01403792

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: P2G12
Description: A single intravaginal administration of 1ml P2G12/placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2G12
Description: A single intravaginal administration of 1ml P2G12/placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2G12
Description: A single intravaginal administration of 1ml P2G12/placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2G12
Description: A single intravaginal administration of 1ml P2G12/placebo.
Study: NCT02094794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total marrow irradiation
Description: Undergo TMLI
Study: NCT00820508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHR-2845
Description: Once daily oral ingestion of capsules (10, 40 or 80mg), dose depending on cohort, treatment cycle of 28 days
Study: NCT00800618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02413873 100 mg QD
Description: 100 mg of PF-02413873 oral suspension once daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02413873 1500 mg QD
Description: 1500 mg of PF-02413873 oral suspension once daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02413873 20 mg QD
Description: 20 mg of PF-02413873 oral suspension once daily for 14 days
Study: NCT02094794

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic peripheral blood stem cell or bone marrow transplant
Study: NCT00970710

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vaasa Childhood Obesity Primary Prevention Study
Description: Intensified counselling concerning healthy diet and suitable physical activity during pregnancy to mothers in the intervention group continuing in child health care clinic visits with the offspring until child's age of 5 year.
Study: NCT02094794

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: Undergo allogeneic peripheral blood stem cell or bone marrow transplant
Study: NCT02808884

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Circulating tumor DNA assay
Description: Blood samples will be separated into plasma and cellular fraction including erythrocytes and buffy coat.The plasma fraction will be placed in a separate tube and frozen for subsequent analysis. Frozen plasma samples, de-identified, will be delivered to Pathway Genomics where DNA content will be analyzed with a circulating tumor DNA assay employing the UBC/Boreal Genomics enrichment technology. All of the participants' plasma will be sent to Pathway, where it will be used up in the assay. Circulating tumor DNA assay results (raw sequencing data) from Pathway Genomics will be returned to UBC and analyzed for the presence of cancer mutations. Any samples showing activating mutations above the assay's technical Limit of Detection (LOD) will be called positive. One exception will be made for TP53 mutations that are known to exist in some normal individuals at low levels. For these mutations, a level of 0.1% will be set, above which the sample will be called positive.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Circulating tumor DNA assay
Description: Blood samples will be separated into plasma and cellular fraction including erythrocytes and buffy coat.The plasma fraction will be placed in a separate tube and frozen for subsequent analysis. Frozen plasma samples, de-identified, will be delivered to Pathway Genomics where DNA content will be analyzed with a circulating tumor DNA assay employing the UBC/Boreal Genomics enrichment technology. All of the participants' plasma will be sent to Pathway, where it will be used up in the assay. Circulating tumor DNA assay results (raw sequencing data) from Pathway Genomics will be returned to UBC and analyzed for the presence of cancer mutations. Any samples showing activating mutations above the assay's technical Limit of Detection (LOD) will be called positive. One exception will be made for TP53 mutations that are known to exist in some normal individuals at low levels. For these mutations, a level of 0.1% will be set, above which the sample will be called positive.
Study: NCT00800618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02413873 500 mg QD
Description: 500 mg of PF-02413873 oral suspension once daily for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-02413873 Placebo
Description: PF-0241383 Placebo once daily for 14 days
Study: NCT03878264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT118335 Oral
Description: CORT118335 900 mg spray-dried dispersion in bottle and vehicle for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-CORT118335 intravenous
Description: 14C-CORT118335 solution for infusion 100 µg containing not more than 37 kiloBequerel (1 µCi) 14C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-CORT118335 oral
Description: 14C-CORT118335 oral solution 150 mg containing not more than 3.3 megaBequerel (90 µCi) 14C
Study: NCT02093871

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ThermalCore Hyperthermia System
Description: Patients will undergo 6 cycles of therapeutic hyperthermia with the ThermalCore Perfusion Induced Systemic Hyperthermia System every 28 days
Study: NCT02808884

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Circulating tumor DNA assay
Description: Blood samples will be separated into plasma and cellular fraction including erythrocytes and buffy coat.The plasma fraction will be placed in a separate tube and frozen for subsequent analysis. Frozen plasma samples, de-identified, will be delivered to Pathway Genomics where DNA content will be analyzed with a circulating tumor DNA assay employing the UBC/Boreal Genomics enrichment technology. All of the participants' plasma will be sent to Pathway, where it will be used up in the assay. Circulating tumor DNA assay results (raw sequencing data) from Pathway Genomics will be returned to UBC and analyzed for the presence of cancer mutations. Any samples showing activating mutations above the assay's technical Limit of Detection (LOD) will be called positive. One exception will be made for TP53 mutations that are known to exist in some normal individuals at low levels. For these mutations, a level of 0.1% will be set, above which the sample will be called positive.
Study: NCT02671292

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy
Description: IPT-WG involves one initial 1.5-hour individual session, and 12 weekly 90-minute group sessions. The IPT-WG group sessions follow 3 phases (initial, middle, and termination) and use the interpersonal inventory to identify interpersonal problems that might be contributing to or exacerbated by LOC eating. A framework of common problem areas is used to teach interpersonal problem-solving and communication skills and educate youth about risk factors for excessive weight gain and warning signs such as eating in response to negative affect as opposed to hunger, or feeling a sense of LOC while eating.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: The HE group is based upon the HEY-Durham health program designed by researchers at Duke University. This program, designed to be delivered to youth attending community high schools, was adapted to a 12-week program (each session is 90 minutes). Additionally, individuals will attend a pre-group individual meeting with the group leaders to review family health history.The curriculum includes focus on various health topics, including alcohol, drug and tobacco use, depression and suicide, nutrition and body image, nonviolent conflict resolution, sun safety, exercise, and domestic violence. Session content will be largely identical for boys and girls, with the exception of gender-specific videos and articles (e.g., on body image), which will be tailored for each sex.
Study: NCT02486354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: icotinib
Description: Patients were administered with oral icotinib (tablet form, 125 mg) three times daily within two days after enrollment until disease progression or unacceptable toxicity.
Study: NCT01093534

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching solifenacin placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching solifenacin placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin
Description: Tablet for oral administration
Study: NCT00085124

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01436916

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral cholecalciferol + life style counselling
Description: oral cholecalciferol 600000 units loading then 60000 units fortnightly for 6months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo + life style counselling
Description: Will provide placebo 10 sachets loading and then single sachet fortnightly for 6 months
Study: NCT01791868

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: According to randomization arm, patients will be treated either by intravenous sodium valproate (30 mg/kg during 15 min then 1 mg/kg/h during 12 h) or intravenous placebo. All included patients will benefit from first-line anti epileptic drugs and symptomatic medical care, in agreement with the French Experts Recommendation 2009(RFE 2009).
Study: NCT04487288

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SONAZOID
Description: CEUS using SONAZOID with fusion technique
Study: NCT02702986

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immunostimulating Interstitial Laser Thermotherapy
Description: Through a laparotomy a laser device will be inserted into the locally advanced pancreatic cancer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser
Study: NCT04043819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSC-01
Description: PSC-01 is a form of autologous cellular therapy resulting from the enzymatic processing of lipoaspirate to yield adipose-derived stromal vascular fraction cells.
Study: NCT02209675

Intervention type: OTHER
Group type: OTHER
Intervention: liver biopsy
Description: C4d assessment by immunohistchemistry in liver biopsy
Study: NCT00200746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine
Description: Amino Acid Arginine
Study: NCT00498316

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cord Blood Infusion
Description: Cord blood transplantation performed on day 0.

Intervention type: DRUG
Group type: OTHER
Intervention: Busulfan
Description: 32 mg/m2 by vein as an outpatient before Day -14 or as an inpatient on Day -9, and AUC of 4,000 microMol.min-1 by vein on Days -7 to -4 for patients with ALL, AML, NHL, CLL, CML, HD, and MM who are \>1 and \< 55 years old. Patients \>55 but \< 65 years who have a Performance Status of 0 or 1 and no comorbidities may receive the myeloablative regimen 4 at the discretion of the investigator(s).
Study: NCT00200746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine
Description: Amino Acid Arginine

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Arginine
Description: Amino Acid Arginine
Study: NCT03238742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xuebijing Injection
Description: 100ml Xuebijing Injection every 12 hours for 5 days
Study: NCT01344655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atimos®
Description: Formoterol 12 μg pMDI
Study: NCT03938376

Intervention type: DIAGNOSTIC_TEST
Intervention: Micro-Ultrasound guided biopsy
Description: High-resolution imaging device
Study: NCT03238742

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 200ml normal saline every 12 hours for 5 days
Study: NCT01344655

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Serevent™
Description: Salmeterol 25 µg pMDI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT03250429

Intervention type: PROCEDURE
Intervention: Sinus surgery
Description: Standard Clinical Sinus Surgery
Study: NCT05768971

Intervention type: OTHER
Intervention: Mild diet

Intervention type: OTHER
Intervention: Mild diet

Intervention type: OTHER
Intervention: Provocative diet

Intervention type: OTHER
Intervention: Provocative diet
Study: NCT04625790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: Transcranial Magnetic Stimulation(TMS) has been used for diagnostic and therapeutic purposes in the treatment of many neurological and psychiatric diseases such as stroke, multiple sclerosis, myelopathy, amyotrophic lateral sclerosis, movement disorders, epilepsy, and depression. It is a way to stimulate the targeted areas in the cerebral cortex without invasive methods. The application of TMS in the aphasia usually consists of repetitive stimulations, in order to activate or deactivate the target area.~In this study, 10 sessions of 1-Hz low frequency rTMS for 20 minutes will be applied to the inferior frontal gyrus of the right frontal lobe.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Speech therapy
Description: Speech therapy will be given to each patient by the same therapist, and the treatment will last 10 days, 60 minutes a day. It will consist of exercises to improve the articulation and comprehension.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speech therapy
Description: Speech therapy will be given to each patient by the same therapist, and the treatment will last 10 days, 60 minutes a day. It will consist of exercises to improve the articulation and comprehension.
Study: NCT00145704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bisphosphonate therapy (risedronate)
Description: Bisphosphonate therapy given to patients with growth hormone deficiency

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D supplement
Description: Vitamin D given to patients with growth hormone deficiency

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D supplement
Description: Vitamin D given to patients with growth hormone deficiency

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: calcium supplement given to patients with growth hormone deficiency

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium
Description: calcium supplement given to patients with growth hormone deficiency
Study: NCT04447417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab SAR231893
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous
Study: NCT01614600

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nelfilcon A contact lenses
Description: Commercially marketed hydrogel contact lenses for daily wear, daily disposable use
Study: NCT04618692

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Loupes
Description: Biliary reconstruction will be performed using surgical loupe

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Microscope
Description: Biliary reconstruction will be performed using microscope
Study: NCT01180374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Active Cannabidiol 5mg.
Study: NCT00729755

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate
Description: In addition to 10-20mg escitalopram, the subjects will be given total 3 gram of creatine (500mg/capsule) a day in first week and then, 5 gram a day in the rest of the weeks.
Study: NCT01093534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin
Description: Tablet for oral administration
Study: NCT00729755

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In addition to 10-20mg escitalopram, the subjects will be given total 6 capsules of placebo (equal quantities to those of creatine group) a day in first week and then, 10 capsules a day in the rest of the weeks.
Study: NCT03855956

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KB174
Description: KB174 is a novel mixture of oligosaccharides.

Intervention type: OTHER
Group type: OTHER
Intervention: Maltodextrin
Description: Maltodextrin is a commercially available easily digestible polysaccharide.
Study: NCT01645137

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: osteopathic manipulative treatment
Description: Patients from this group received osteopathic treatments twice a week for the entire length of stay in the unit.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
Study: NCT04505735

Intervention type: DRUG
Intervention: 11C-PiB
Description: Pittsburgh Compound-B (11C-PiB) is a diagnostic imaging agent that binds to beta-amyloid plaques and allows them to be viewed using positron emission tomography (PET) imaging.

Intervention type: DRUG
Intervention: 11C-PiB
Description: Pittsburgh Compound-B (11C-PiB) is a diagnostic imaging agent that binds to beta-amyloid plaques and allows them to be viewed using positron emission tomography (PET) imaging.
Study: NCT00905827

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAMS
Description: Collaborative assessment management in suicidality

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAMS
Description: Collaborative assessment management in suicidality
Study: NCT03725215

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Split-Belt Treadmill Training
Description: One session of 6 x 5 min with 1 min intervals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Split-Belt Treadmill Training
Description: One session of 6 x 5 min with 1 min intervals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Split-Belt Treadmill Training
Description: One session of 6 x 5 min with 1 min intervals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Split-Belt Treadmill Training
Description: One session of 6 x 5 min with 1 min intervals.
Study: NCT01892215

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cephalad-caudad expansion
Description: Blunt expansion of the uterine incision by the physician separating the fingers in a cephalad-caudad direction.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversal expansion
Description: Blunt expansion of the uterine incision by the physician separating the fingers in a transversal direction.
Study: NCT00894023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intracoronary bolus wtih ClearWay™RX catheter
Description: Intracoronary bolus with Clearway catheter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV abciximab
Description: IV abciximab + infusion